FOLH1 and prostate carcinoma: Privé et al. (2024) conducted a prospective study of 75 patients reporting that adding 18F-PSMA-1007 PET/CT to mpMRI improved diagnostic accuracy for equivocal PIRADS 3 lesions when correlated with target biopsy results, thereby ruling out clinically significant prostate cancer in 93% of cases.